Blount International Inc. (BLT) Financials Nov 17, 2014,

New Post Public Reply Private Reply Replies (0) Message Board
Hirata
Blount International Inc. (BLT) Financials Nov 17, 2014, 4:23 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Blount International Inc.


Fiscal year is January-December. All values USD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 502.43M 611.48M 831.63M 927.67M 900.6M
Cost of Goods Sold (COGS) incl. D&A 332.93M 407.45M 576.61M 670.38M 641.18M
COGS excluding D&A 306.99M 379.86M 541.81M 625.26M 591.66M
Depreciation & Amortization Expense 25.94M 27.6M 34.8M 45.12M 49.52M
Depreciation 20.4M 20.97M 23.48M 28.59M 33.48M
Amortization of Intangibles 5.55M 6.63M 11.32M 16.53M 16.04M
Gross Income 169.5M 204.03M 255.02M 257.29M 259.42M
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 109.12M 118.47M 153.76M 170.54M 173.52M
Research & Development 8.5M 11M 19.6M 17M 15.2M
Other SG&A 100.62M 107.47M 134.16M 153.54M 158.32M
Other Operating Expense 0 0 0 0 0
Unusual Expense 6.89M 7M 3.31M 7.48M 47.88M
EBIT after Unusual Expense (6.89M) (7M) (3.31M) (7.48M) (47.88M)
Non Operating Income/Expense 2.94M (427,000) (4.45M) (284,000) (2.62M)
Non-Operating Interest Income 206,000 119,000 171,000 158,000 630,000
Equity in Affiliates (Pretax) 0 0 0 0 0
Interest Expense 24.71M 25.64M 18.72M 17.36M 18.47M
Gross Interest Expense 24.71M 25.64M 18.72M 17.86M 18.67M
Interest Capitalized - - - 500,000 200,000
Pretax Income 31.93M 52.61M 74.95M 61.79M 17.56M
Income Tax 8.94M 11.21M 25.27M 22.2M 12.72M
Income Tax - Current Domestic 2.53M 2.63M 17.37M 17.47M 9.09M
Income Tax - Current Foreign 4.27M 4.52M 5.57M 12.33M 9.32M
Income Tax - Deferred Domestic 2.35M 3.29M 906,000 (7.18M) (6.52M)
Income Tax - Deferred Foreign (201,000) 768,000 1.43M (409,000) 833,000
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 0
Other After Tax Income (Expense) - - - 0 0
Consolidated Net Income 22.99M 41.4M 49.68M 39.59M 4.84M
Minority Interest Expense 0 0 0 0 0
Net Income 22.99M 41.4M 49.68M 39.59M 4.84M
Extraordinaries & Discontinued Operations 0 5.8M 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - 0 0 0 0
Discontinued Operations 0 5.8M 0 0 0
Net Income After Extraordinaries 22.99M 47.2M 49.68M 39.59M 4.84M
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 22.99M 41.4M 49.68M 39.59M 4.84M
EPS (Basic) 0.48 0.99 1.02 0.81 0.10
Basic Shares Outstanding 47.76M 47.92M 48.7M 49.17M 49.48M
EPS (Diluted) 0.48 0.97 1.01 0.79 0.10
Diluted Shares Outstanding 48.27M 48.51M 49.43M 49.9M 50.12M
EBITDA 86.32M 113.15M 136.06M 131.87M 135.42M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Delhi Pushes Innovation Against Dryland Challenges

Updated Category News Views 1

Evolution of South-South Agricultural Cooperation Let's just say if there's a time to shine a spotlight on the arid lands of our world, it's now. The Global Drylands Congress 2026 in New Delhi put a sharp focus on scaling agricultural innovation across these thirsty regions. With climate change breathing down our necks, talking shop about food security isn't just for show...

Continue Reading
IASLC Boosts Global Thoracic Cancer Collaboration

Updated Category News Views 2

Breaking Down Barriers in Thoracic Oncology Picture a world where financial walls don't block innovation and knowledge sharing in cancer treatment. The International Association for the Study of Lung Cancer (IASLC) is leading the charge here. They've just launched a new initiative offering complimentary full membership to qualified healthcare professionals in low- and...

Continue Reading
SystImmune's Data on Iza-bren Show Promise for Lung Cancer

Updated Category News Views 6

Stepping into New Territory with SystImmune Amid the cacophony of biotech whispers and the marketplace hum, SystImmune is trotting out something that might just make the folks in lab coats raise an eyebrow. They’ve got new data for Iza-bren—none of that flashy PR chatter—but it's damn promising if you ask me. At the World Conference on Lung Cancer in Seoul,...

Continue Reading
Countries Eye New Investment Paths at CIFIT 2026

Updated Category News Views 3

Global Investment Winds Shift at CIFIT In the thick of a world that's being turned on its head, you've got big shots from 129 countries and 30 international organizations talking shop at the 26th China International Fair for Investment and Trade (CIFIT) in Xiamen. Take your pick from the 48 of the world's top 50 GDP powerhouses rubbing shoulders there—this ain't your...

Continue Reading
PathoSearch: A New Era in Pathology With Visual Search

Updated Category News Views 5

Revolutionizing Pathology with a Visual Search Engine In an era where time is money and precision is paramount, Aignostics is betting big on transforming the pathology landscape. Today, their announcement of PathoSearch, a visual search engine designed for retrieving comparable diagnosed pathology cases, marks a massive leap towards streamlining the diagnostic process....

Continue Reading
ARTiSTORY's Strategic Advance in Cultural IP Licensing

Updated Category News Views 4

Call it a seismic shift or call it common sense, but ARTiSTORY's recent haul of accolades makes it clear: they're onto something big in the cultural IP game. Receiving four honors at the 26th International Advertising Institute Awards (IAI Awards), including a Gold for their British Library × CHAGEE collaboration, and jumping into License Global's Top 60, they're staking...

Continue Reading
Silk Road Maritime Extends Its Global Reach in 2026

Updated Category News Views 3

China-Europe Trade Ties Continue to Tighten You ever watch a cargo ship glide into port and think, "There's a piece of the future right there”? Well, that's the scene at Poland’s Gdansk Port, now officially etched into the Silk Road Maritime route. This ain't just a couple of extra boats cutting through choppy waters—it's a great leap forward for a strained global...

Continue Reading
Nocpix Unveils ACE 2 Thermal Riflescope Lineup

Updated Category News Views 3

ACE 2: A Thermal Riflescope That Promises More Let’s dive right into the nitty-gritty of Nocpix’s latest move. On September 12, they launched the ACE 2 Series—the next-gen beast of their flagship thermal riflescope lineup. A step up from the original ACE, this series aims to redefine what hunters can expect from a riflescope, introducing three models: ACE 2 S60R,...

Continue Reading

Top 5 Most Recently Viewed Articles

Construction Leaders Unite to Combat Worker Suicide Crisis

Updated Category News Views 53

Construction Leaders Unite to Combat Worker Suicide Crisis In a significant move to address the alarming rate of suicide among construction workers, leading CEOs from prominent firms including Bechtel, Fluor, and Turner Construction Company have launched a new CEO Advisory Council. This initiative aims to drive awareness and develop effective solutions for mental health...

Continue Reading
Jack DiFranco Joins Woodward Park Partners Amid Growth Surge

Updated Category News Views 432

New Face, New Opportunities Talk about a shake-up! Woodward Park Partners just snagged Jack DiFranco, a heavyweight in the mergers and acquisitions arena. This isn’t just a name drop; we’re talking about 35 years of serious industry grind under his belt. DiFranco isn't just here to fill a seat; he’s got the chops to elevate this firm into a new realm of...

Continue Reading
BitMine's Ethereum Strategy Surges with $2 Billion in Holdings

Updated Category News Views 267

BitMine's Revolutionary Ethereum Holdings Strategy BitMine Immersion Technologies has achieved a remarkable milestone by surpassing $2 billion in Ethereum (ETH) holdings. This significant increase over the initial $250 million capital raise demonstrates the company's strong asset management and commitment to its treasury strategy. The journey began with a private...

Continue Reading
Fennec Pharmaceuticals Prepares for Q1 2025 Results Announcement

Updated Category News Views 139

Fennec Pharmaceuticals Set to Release Quarterly Financial Results RESEARCH TRIANGLE PARK, N.C. -- Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a dedicated specialty pharmaceutical company, has made an important announcement regarding its first quarter financial results for 2025. The company is on track to unveil these results before the U.S. financial markets...

Continue Reading
Stellantis Faces Lowest Italian Vehicle Production in Decades

Updated Category News Views 376

Stellantis and Its Production Challenges in Italy Stellantis (NYSE: STLA), the result of a major merger between iconic brands, is experiencing a notable decline in vehicle production within Italy. This setback is particularly concerning as it represents the lowest output levels this country has seen since 1956. Declining Production Figures Reported Recent data from union...

Continue Reading